Study of NGM313 in Obese Participants

Completed · Phase 1

Conditions studied: Obese

In brief

The purpose of the study is to evaulate the safety, tolerability, and efficacy of NGM313 in obese participants

Key facts

Study ID

NCT03298464

Run by

NGM Biopharmaceuticals, Inc

People needed

25

Starts

2017-09-11

Expected to finish

2018-07-17

Last updated by the study team

2019-03-13

Who can join

Age: 21 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Body mass index (BMI) of 30-43 kg/m2
• Waist circumference > 40 inches in males or > 30 inches in females
• Normal ECG readings

You may not qualify if…

• Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder
• History of any known Congestive heart failure (CHF)
• History of macrovascular disease

Where it is running

• Prosciento — Chula Vista, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.